Market News AIOpen the app

CRISPR Therapeutics Presents Positive Phase 1b Clinical Data for CTX310

TrialRead the original at globenewswire.com
Good for CRSP

The Phase 1b study reported 65% lower ANGPTL3 and 63% lower triglycerides after one course of CTX310. It remains experimental, so patient benefit and approval are not yet established.

CRSP · CRISPR Therapeutics

AI read · Good for CRSP

The AI's read

These findings give the company encouraging evidence for a treatment aimed at severe high triglycerides. The FDA designations may help its development. The results are blood measurements from an early study, not proof that patients feel better or that the treatment will be approved.

Get alerts for CRSP

Follow CRISPR Therapeutics (CRSP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CRSP
Free on the App Store and Google Play, or on the web.